{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:51:19Z","timestamp":1782989479591,"version":"3.54.5"},"reference-count":44,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0064","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:13:25Z","timestamp":1782987205000},"source":"Crossref","is-referenced-by-count":0,"title":["Direct oral anticoagulants versus phenprocoumon: Mortality, thromboembolism and major hemorrhage. A systematic review and meta-analysis of routine data studies"],"prefix":"10.3238","author":[{"given":"Christiane","family":"Engelbertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"K\u00f6ppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"10.3238\/arztebl.m2026.0064_ref1","doi-asserted-by":"crossref","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al..: 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45: 3314\u2013414","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"10.3238\/arztebl.m2026.0064_ref2","doi-asserted-by":"crossref","unstructured":"Steffel J, Verhamme P, Potpara TS, et al..: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oret al. anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330\u201393","DOI":"10.5603\/KP.2018.0180"},{"key":"10.3238\/arztebl.m2026.0064_ref3","unstructured":"Deutsche Gesellschaft f\u00fcr Kardiologie: S3-Leitlinie Vorhofflimmern \u2013 Version 1. https:\/\/register.awmf.org\/assets\/guidelines\/019-014l_S3_Vorhofflimmern_2025-07.pdf (last accessed on 19 May 2026)."},{"key":"10.3238\/arztebl.m2026.0064_ref4","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139\u201351","DOI":"10.1056\/NEJMoa0905561"},{"key":"10.3238\/arztebl.m2026.0064_ref5","doi-asserted-by":"crossref","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883\u201391","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.3238\/arztebl.m2026.0064_ref6","doi-asserted-by":"crossref","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981\u201392","DOI":"10.1056\/NEJMoa1107039"},{"key":"10.3238\/arztebl.m2026.0064_ref7","doi-asserted-by":"crossref","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093\u2013104","DOI":"10.1056\/NEJMoa1310907"},{"key":"10.3238\/arztebl.m2026.0064_ref8","doi-asserted-by":"crossref","unstructured":"Pirmohamed M: Warfarin: Almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62: 509\u201311","DOI":"10.1111\/j.1365-2125.2006.02806.x"},{"key":"10.3238\/arztebl.m2026.0064_ref9","doi-asserted-by":"crossref","unstructured":"Le Heuzey JY, Ammentorp B, Darius H, et al.: Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833\u201341","DOI":"10.1160\/TH13-12-1007"},{"key":"10.3238\/arztebl.m2026.0064_ref10","doi-asserted-by":"crossref","unstructured":"Stehle S, Kirchheiner J, Lazar A, Fuhr U: Pharmacogenetics of oral anticoagulants: A basis for dose individualization. Clin Pharmacokinet 2008; 47: 565\u201394","DOI":"10.2165\/00003088-200847090-00002"},{"key":"10.3238\/arztebl.m2026.0064_ref11","doi-asserted-by":"crossref","unstructured":"Bonnemeier H, Huelsebeck M, Kloss S: Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany\u2014a retrospective cohort study. Int J Cardiol Heart Vasc 2019; 23: 100367","DOI":"10.1016\/j.ijcha.2019.100367"},{"key":"10.3238\/arztebl.m2026.0064_ref12","doi-asserted-by":"crossref","unstructured":"Engelbertz C, Marschall U, Feld J, et al.: Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin-K antagonists: A retrospective German claims data analysis. J Intern Med 2024; 296: 362\u201376","DOI":"10.1111\/joim.20006"},{"key":"10.3238\/arztebl.m2026.0064_ref13","doi-asserted-by":"crossref","unstructured":"Hohmann C, Lutz M, Vignali S, et al.: Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: A German real-world cohort study. Thromb J 2022; 20: 37","DOI":"10.1186\/s12959-022-00395-x"},{"key":"10.3238\/arztebl.m2026.0064_ref14","doi-asserted-by":"crossref","unstructured":"Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R: Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost 2019; 119: 971\u201380","DOI":"10.1055\/s-0039-1683422"},{"key":"10.3238\/arztebl.m2026.0064_ref15","doi-asserted-by":"crossref","unstructured":"Hohnloser SH, Basic E, Nabauer M: Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: A post-marketing surveillance study. Clin Res Cardiol 2017; 106: 618\u201328","DOI":"10.1007\/s00392-017-1098-x"},{"key":"10.3238\/arztebl.m2026.0064_ref16","doi-asserted-by":"crossref","unstructured":"Hohnloser SH, Basic E, Hohmann C, Nabauer M: Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: Data from 61,000 patients with atrial fibrillation. Thromb Haemost 2018; 118: 526\u201338","DOI":"10.1160\/TH17-10-0733"},{"key":"10.3238\/arztebl.m2026.0064_ref17","doi-asserted-by":"crossref","unstructured":"Kreutz R, Kloss S, Enders D, et al.: Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation. Int J Cardiol 2024; 404: 131894","DOI":"10.1016\/j.ijcard.2024.131894"},{"key":"10.3238\/arztebl.m2026.0064_ref18","doi-asserted-by":"crossref","unstructured":"Mueller S, Groth A, Spitzer SG, Schramm A, Pfaff A, Maywald U: Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: A cohort study based on a German claims dataset. Pragmat Obs Res 2018; 9: 1\u201310","DOI":"10.2147\/POR.S156521"},{"key":"10.3238\/arztebl.m2026.0064_ref19","doi-asserted-by":"crossref","unstructured":"Paschke LM, Klimke K, Altiner A, von Stillfried D, Schulz M: Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A nationwide retrospective observational study. BMC Med 2020; 18: 254","DOI":"10.1186\/s12916-020-01695-7"},{"key":"10.3238\/arztebl.m2026.0064_ref20","doi-asserted-by":"crossref","unstructured":"Preinreich J, Sheikh Rezaei S, Mittlb\u00f6ck M, Greisenegger S, Reichardt B, Wolzt M: Oral anticoagulant therapy and outcome in patients with stroke. A retrospective nation-wide cohort study in Austria 2012\u20132017. Pharmacoepidemiol Drug Saf 2021; 30: 1332\u20138","DOI":"10.1002\/pds.5296"},{"key":"10.3238\/arztebl.m2026.0064_ref21","doi-asserted-by":"crossref","unstructured":"Ujeyl M, K\u00f6ster I, Wille H, et al.: Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. Eur J Clin Pharmacol 2018; 74: 1317\u201325","DOI":"10.1007\/s00228-018-2504-7"},{"key":"10.3238\/arztebl.m2026.0064_ref22","doi-asserted-by":"crossref","unstructured":"Warkentin L, Hueber S, Deiters B, Klohn F, K\u00fchlein T: Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: A real-world analysis of German claims data. Thromb J 2022; 20: 31","DOI":"10.1186\/s12959-022-00389-9"},{"key":"10.3238\/arztebl.m2026.0064_ref23","doi-asserted-by":"crossref","unstructured":"Warkentin L, Klohn F, Deiters B, K\u00fchlein T, Hueber S: Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: A real-world analysis of German claims data. BMJ Open 2023; 13: e063490","DOI":"10.1136\/bmjopen-2022-063490"},{"key":"10.3238\/arztebl.m2026.0064_ref24","doi-asserted-by":"crossref","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al.: Real-world evidence\u2014what is it and what can it tell us? N Engl J Med 2016; 375: 2293\u20137","DOI":"10.1056\/NEJMsb1609216"},{"key":"10.3238\/arztebl.m2026.0064_ref25","doi-asserted-by":"crossref","unstructured":"Camm AJ, Fox KAA: Strengths and weaknesses of \u201areal-world\u2018 studies involving non-vitamin K antagonist oral anticoagulants. Open Heart 2018; 5: e000788","DOI":"10.1136\/openhrt-2018-000788"},{"key":"10.3238\/arztebl.m2026.0064_ref26","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.: ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"10.3238\/arztebl.m2026.0064_ref27","doi-asserted-by":"crossref","unstructured":"Chan YH, Chen SW, Chan CY, Chao TF: Comparative safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation: A network meta-analysis. J Formos Med Assoc 2024; 123: 578\u201386","DOI":"10.1016\/j.jfma.2023.10.014"},{"key":"10.3238\/arztebl.m2026.0064_ref28","doi-asserted-by":"crossref","unstructured":"Deitelzweig S, Bergrath E, di Fusco M, et al.: Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: A systematic review and network meta-analysis. Future Cardiol 2022; 18: 393\u2013405","DOI":"10.2217\/fca-2021-0120"},{"key":"10.3238\/arztebl.m2026.0064_ref29","doi-asserted-by":"crossref","unstructured":"Coleman CI, Briere JB, Fauchier L, et al..: Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy 2019; 7: 1574541","DOI":"10.1080\/20016689.2019.1574541"},{"key":"10.3238\/arztebl.m2026.0064_ref30","doi-asserted-by":"crossref","unstructured":"Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH: Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: A systematic review and meta-analysis. Stroke 2017; 48: 2494\u2013503","DOI":"10.1161\/STROKEAHA.117.017549"},{"key":"10.3238\/arztebl.m2026.0064_ref31","doi-asserted-by":"crossref","unstructured":"Kreis K, Neubauer S, Klora M, Lange A, Zeidler J: Status and perspectives of claims data analyses in Germany\u2014a systematic review. Health Policy 2016; 120: 213\u201326","DOI":"10.1016\/j.healthpol.2016.01.007"},{"key":"10.3238\/arztebl.m2026.0064_ref32","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Outes A, Terleira-Fern\u00e1ndez AI, Calvo-Rojas G, Su\u00e1rez-Gea ML, Vargas-Castrill\u00f3n E: Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: Meta-analysis by geographic region with a focus on European patients. Br J Clin Pharmacol 2016; 82: 633\u201344","DOI":"10.1111\/bcp.13005"},{"key":"10.3238\/arztebl.m2026.0064_ref33","doi-asserted-by":"crossref","unstructured":"Camm AJ, Cools F, Virdone S, et al.: Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 2020; 76: 1425\u201336","DOI":"10.1016\/j.jacc.2020.07.045"},{"key":"10.3238\/arztebl.m2026.0064_ref34","doi-asserted-by":"crossref","unstructured":"M\u00fchlbauer B, Ludwig WD: Arzneiverordnungen 2023 im \u00dcberblick. In: Ludwig WD, M\u00fchlbauer B, Seifert R (eds.): Arzneiverordnungs-Report 2024. Springer Berlin, Heidelberg, 2025; 11\u201315","DOI":"10.1007\/978-3-662-70594-0_1"},{"key":"10.3238\/arztebl.m2026.0064_ref35","doi-asserted-by":"crossref","unstructured":"Rodman T, Pastor BH, Resnick M. Phenprocoumon, diphenadione, warfarin and bishydroxycoumarin: A comparative study. Am J Med Sci. 1964; 247: 655\u2013660","DOI":"10.1097\/00000441-196406000-00003"},{"key":"10.3238\/arztebl.m2026.0064_ref36","unstructured":"van Leeuwen Y, Gebuis EPA, van der Meer FJM, Rosendaal FR. Late breaking clinical trial: randomised comparison of the quality of anticoagulant therapy with two vitamin K antagonists: warfarin versus phenprocoumon. J Thromb Haemost. 2009; 7: 1202. LB-MO-001."},{"key":"10.3238\/arztebl.m2026.0064_ref37","doi-asserted-by":"crossref","unstructured":"Jensen CF, Christensen TD, Maegaard M, Hasenkam JM. Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon. J Thromb Thrombolysis 2009; 28: 276\u2013281","DOI":"10.1007\/s11239-008-0274-2"},{"key":"10.3238\/arztebl.m2026.0064_ref38","doi-asserted-by":"crossref","unstructured":"Leiria TL, Pellanda L, Miglioranza MH, Sant\u2018anna RT, Becker LS, Magalh\u00e3es E, Lima GG. [Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic]. Arq Bras Cardiol 2010; 94: 41\u201345","DOI":"10.1590\/S0066-782X2010000100008"},{"key":"10.3238\/arztebl.m2026.0064_ref39","doi-asserted-by":"crossref","unstructured":"Schl\u00f6glhofer T, Marsch\u00fctz A, Combs P, Stonebraker C, Lupo S, Jeevanandam V, Riebandt J, Schima H, Zimpfer D, Meehan K. Quality of Anticoagulation With Phenprocoumon and Warfarin in Left Ventricular Assist Device Patients: A Multicenter Study. ASAIO J 2023; 69: 595\u2013601","DOI":"10.1097\/MAT.0000000000001895"},{"key":"10.3238\/arztebl.m2026.0064_ref40","doi-asserted-by":"crossref","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al.: A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation 2023; 147: 296\u2013309","DOI":"10.1161\/CIRCULATIONAHA.122.062779"},{"key":"10.3238\/arztebl.m2026.0064_ref41","doi-asserted-by":"crossref","unstructured":"Andreas M, Moayedifar R, Wieselthaler G, et al.: Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial. Circ Heart Fail 2017; 10: e003709","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709"},{"key":"10.3238\/arztebl.m2026.0064_ref42","doi-asserted-by":"crossref","unstructured":"Joosten LPT, van Doorn S, van de Ven PM, et al.: Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation 2024; 149: 279\u2013289","DOI":"10.1161\/CIRCULATIONAHA.123.066485"},{"key":"10.3238\/arztebl.m2026.0064_ref43","doi-asserted-by":"crossref","unstructured":"Ferner M, Wachtlin D, Konrad T, et al.: Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol 2016; 105: 29\u201336","DOI":"10.1007\/s00392-015-0883-7"},{"key":"10.3238\/arztebl.m2026.0064_ref44","doi-asserted-by":"crossref","unstructured":"Riesinger L, Strobl C, Leistner DM, et al.: Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting. Int J Cardiol Heart Vasc 2021; 35: 100810","DOI":"10.1016\/j.ijcha.2021.100810"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:15:19Z","timestamp":1782987319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":44,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0064","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}